Phase III study of investigational TRILIPIX™ (SLV348/ABT-335), in combination with Astrazeneca’s CRESTOR® meets primary endpoints on key lipids

TriLipix™ in combination with Crestor® improved LDL, HDL and Triglycerides and had reported safety consistent with monotherapies